{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:29:21Z","timestamp":1791250161951,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":3116,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1038\/modpathol.2013.206","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T07:44:45Z","timestamp":1386315885000},"page":"1028-1034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"title":["BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"27","author":[{"given":"Benjamin","family":"Goeppert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Frauenschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Klauschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Warth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika Nadja","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianeb","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Hafezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Boehmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"von Deimling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilko","family":"Weichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Capper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2013.206_bib1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nrgastro.2011.131","article-title":"Clinical diagnosis and staging of cholangiocarcinoma","volume":"8","author":"Blechacz","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1038\/modpathol.2013.206_bib2","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2009.27.4787","article-title":"Genetics of biliary tract cancers and emerging targeted therapies","volume":"28","author":"Hezel","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2013.206_bib3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","article-title":"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1038\/modpathol.2013.206_bib4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.onc.1210704","article-title":"BRAF(E600) in benign and malignant human tumours","volume":"27","author":"Michaloglou","year":"2008","journal-title":"Oncogene"},{"key":"10.1038\/modpathol.2013.206_bib5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1038\/modpathol.2013.206_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/sj.bjc.6606030","article-title":"Targeting BRAF for patients with melanoma","volume":"104","author":"Arkenau","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1038\/modpathol.2013.206_bib7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2013.206_bib8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2013.206_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1038\/modpathol.2013.206_bib10","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1200\/JCO.2012.44.1568","article-title":"Brainstem ganglioglioma successfully treated with vemurafenib","volume":"31","author":"Rush","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2013.206_bib11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1089\/thy.2013.0057","article-title":"Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring V600EBRAF mutation","volume":"23","author":"Kim","year":"2013","journal-title":"Thyroid"},{"key":"10.1038\/modpathol.2013.206_bib12","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1038\/modpathol.2013.206_bib13","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMc1202124","article-title":"BRAF inhibition in refractory hairy-cell leukemia","volume":"366","author":"Dietrich","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2013.206_bib14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","article-title":"Targeting the BRAF V600E mutation in multiple myeloma","volume":"3","author":"Andrulis","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1038\/modpathol.2013.206_bib15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaad.2012.03.022","article-title":"Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1","volume":"67","author":"Skorokhod","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/modpathol.2013.206_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","article-title":"Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma","volume":"37","author":"Long","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2013.206_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmoldx.2012.09.001","article-title":"Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing","volume":"15","author":"Colomba","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1038\/modpathol.2013.206_bib18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/jclinpath-2013-201483","article-title":"A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma?","volume":"66","author":"Lade-Keller","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1038\/modpathol.2013.206_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/PAS.0b013e318271249e","article-title":"Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions","volume":"37","author":"Busam","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2013.206_bib20","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/PAS.0b013e318246b527","article-title":"Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma","volume":"36","author":"Koperek","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2013.206_bib21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/ERC-12-0239","article-title":"Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma","volume":"19","author":"Bullock","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1038\/modpathol.2013.206_bib22","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1097\/PAS.0b013e31828f233d","article-title":"BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch Syndrome","volume":"37","author":"Toon","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2013.206_bib23","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ijc.28183","article-title":"BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer","volume":"133","author":"Capper","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1038\/modpathol.2013.206_bib24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00401-013-1100-2","article-title":"Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells","volume":"125","author":"Koelsche","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1038\/modpathol.2013.206_bib25","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1097\/PAS.0b013e3182549b50","article-title":"Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia","volume":"36","author":"Andrulis","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2013.206_bib26","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.humpath.2012.11.006","article-title":"Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions","volume":"44","author":"Voss","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1038\/modpathol.2013.206_bib27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","article-title":"Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes","volume":"144","author":"Sia","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1038\/modpathol.2013.206_bib28","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1038\/modpathol.2013.206_bib29","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"key":"10.1038\/modpathol.2013.206_bib30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00428-004-1046-9","article-title":"Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability","volume":"445","author":"Saetta","year":"2004","journal-title":"Virchows Arch"},{"key":"10.1038\/modpathol.2013.206_bib31","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/modpathol.3800204","article-title":"The V599E BRAF mutation is uncommon in biliary tract cancers","volume":"17","author":"Goldenberg","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2013.206_bib32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"10.1038\/modpathol.2013.206_bib33","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"10.1038\/modpathol.2013.206_bib34","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2013.206_bib35","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mds534","article-title":"Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients","volume":"24","author":"Ilie","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2013.206_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-011-0887-y","article-title":"Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases","volume":"123","author":"Capper","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1038\/modpathol.2013.206_bib37","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1038\/modpathol.2013.206_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2407-13-17","article-title":"Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D\/R) mutations","volume":"13","author":"Gentilcore","year":"2013","journal-title":"BMC Cancer"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol2013206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2013206","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222018865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222018865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2013206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:54:05Z","timestamp":1760230445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222018865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0893395222018865"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2013.206","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2013.206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}